Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.

BACKGROUND: Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. OBJECTIVE: To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. ANIMALS: Forty-nine client-owned dogs with CKD. METHODS: Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. RESULTS: No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53-575) days in the benazepril group and 287 (152-not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21-1.22) with P = .12 for initial urine protein-to-creatinine ratio (UPC) >0.5, and 0.38 (0.12-1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 µmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. CONCLUSIONS AND CLINICAL RELEVANCE: Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.

Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.

OBJECTIVES: To retrospectively evaluate the clinical response and toxicity associated with masitinib mesylate (Masivet®) treatment of macroscopic mast cell tumours in the dog. METHODS: Retrospective review of medical records of 39 dogs that had undergone treatment with masitinib for macroscopic mast cell tumours. Patient signalment, tumour location, tumour grade, tumour stage, previous treatments, concurrent medications, dose of masitinib, side effects, response, time to tumour progression, survival time and cause of death were documented. Response was assessed according to RECIST criteria. RESULTS: Clinical response was observed in 32 (82·1%) dogs receiving masitinib, with 15 dogs (38·5%) exhibiting a complete response and 17 dogs (43·6%) achieving a partial response. The median time to progression was 79 days (range: 14 to 667 days). Adverse effects were seen in 25 dogs (64·1%) with serum alanine aminotransferase elevation (n=9; 23·1%) and vomiting (n=6; 15·4%) being most common. Median survival time following initiation of masitinib was 159 days (range: 14 to 1339). CLINICAL SIGNIFICANCE: Masitinib appears to be a well-tolerated and effective drug against macroscopic mast cell tumours.

Probable cutaneous hypersensitivity to carboplatin single-agent chemotherapy in a dog.

Carboplatin is usually a well-tolerated drug and has many applications in veterinary oncology. The side effects of carboplatin described in the veterinary literature include myelotoxicity, nephrotoxicity, digestive and appetite disorders. In 114 dogs treated by single-agent chemotherapy with carboplatin, we observed a rate of non-haematological toxicities of 19·3% (personal observation). This case report describes the first case of cutaneous delayed-hypersensitivity to carboplatin in a dog, diagnosed according to the official ABON-system, which determines a causal association between a suspected product and a reported reaction (A=probable, B=possible, O=unclassifiable and N=unlikely), and an experimental intradermal skin test. Antihistamines were used to treat the reaction, and future carboplatin treatments were adjusted by premedication with corticosteroids, prolonged infusion and a reduction of 20% of the first dose of carboplatin. No further reactions were noted during the following treatments.

A multicentric retrospective study of serum/plasma urea and creatinine concentrations in dogs using univariate and multivariate decision rules to evaluate diagnostic efficiency.

BACKGROUND: Urea and creatinine are the most frequently used indirect markers in plasma and serum of glomerular filtration rate in dogs. Both have been shown to lack sensitivity but their diagnostic efficiency for the diagnosis of kidney disease has been minimally investigated. OBJECTIVE: The purpose of this retrospective study was to investigate the influence of possible factors of variation on both analytes and to determine whether specific decision rules should be drawn up for subpopulations of dogs. METHODS: The results of urea and creatinine measurements, breed, sex, age, and health status (healthy, renal disease, or nonrenal disease) of 3822 dogs were collected from the archives of 5 veterinary clinics. Data were analyzed with univariate and multivariate decision rules with and without adjustment. RESULTS: There were significant effects and interactions of almost all of the sources of variation. Slight improvements in diagnostic efficiency were obtained by adjusting the decision rules to these sources of variations. Univariate decision rules gave approximately the same diagnostic efficiency for urea and creatinine concentrations, with sensitivity and specificity in the range of 70% and 90%, respectively, using the upper limit of the reference interval as the threshold value. Multivariate decision rules provided only minor improvements in diagnostic efficiency. CONCLUSION: Simultaneous measurement of both urea and creatinine is of limited diagnostic value over the analysis of a single variable. Creatinine is the preferred analyte as it is affected by fewer extrarenal factors of variation.

Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside.

The records of 11 dogs with evidence of meningoencephalomyelitis of unknown origin were reviewed. Two of them had had a focal form of the disease and the other nine a disseminated form. The forebrain was involved in five of the nine dogs with disseminated disease, the brainstem in all nine and the cerebellum in one. They had been treated with courses of cytosine arabinoside every three weeks and immunosuppressive doses of prednisolone. Their response to the treatment, in terms of quality of life, was judged by their owners and referring veterinarians to have been excellent in five, good in five and poor in one; their survival times ranged from 78 days to more than 603 days. The cumulative probability of survival at two years was 58.4 per cent. No signs of myelosuppression or other side effects associated with cytosine arabinoside were observed.

Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.

Vinblastine toxicity is poorly documented in dogs. The aim of this study was to investigate the haematological alterations in dogs treated with vinblastine and prednisolone. Fourteen dogs with mast cell tumours (MCT) were selected on at least one of the following criteria: lymph node infiltration, surgical margin infiltration, grade II MCTs with Ki-67 >10%, and grade III MCTs. Starting 15 days after surgery, the dogs were given vinblastine (2 mg/m2 i.v. four times weekly, then twice monthly for 2 months) and prednisolone (2 mg/kg/day p.o.). An EDTA blood sample was collected weekly for complete blood count (CBC). A total of 98 doses of vinblastine were given to the 14 dogs and 114 CBC were performed. Abnormal haematological findings were observed in 12 CBCs from five dogs, which represent a prevalence of 20% of the total CBCs performed in these animals. The most prevalent abnormal finding was thrombopenia (9/12) most often with grade I toxicity (6/9). In conclusion, the risk of occurrence of adverse haematological effects resulting from vinblastine-prednisolone treatment seems limited in dogs with MCT and it should not be overestimated.

Chemical and structural changes in dry-cured hams (Bayonne hams) during processing and effects of the dehairing technique.

Pigs of similar genetic backgrounds and feeding regimes were slaughtered in two abattoirs, one carrying out dehairing by scalding and the other by singeing. One ham from each of 80 carcasses was retained. Sixteen fresh hams (8 from each dehairing technique) were used for analysis while 64 hams were processed into dry-cured ham. Sixteen hams (8 from each dehairing technique) were taken for analysis at end of salting (day 14), end of rest (day 78), mid-processing (day 127) and end of processing (day 251). During processing, the water content of all muscles decreased while the salt content increased. The salt concentration in muscle water tended to equalize in all muscles. The nitrogen content of desalted dry matter (i.e. dry muscle tissue) decreased in both Biceps femoris and Semimembranosus. The content of every free amino acid increased with time, except for taurine and glutamine. Electrophoresis of the low ionic strength-soluble fractions showed all protein bands decreased during processing. Electrophoresis of the myofibrillar fractions indicated changes in all bands except actin (42kDa). These changes were more marked in the Semimembranosus than the Biceps femoris in the earlier processing steps. Ultrastructural changes were more marked in Semimembranosus than Biceps femoris. Hardness and chewiness increased in both muscles during the first half of processing then returned to values close to the initial ones in Semimembranosus but changed little in Biceps femoris. The scalded hams lost more weight than the singed ones during processing. The salt content was higher in scalded hams. Water-soluble nitrogen and NPN were higher in singed hams at the end of processing. The scalded hams were saltier and pungent. They had more pronounced aromas of dry ham, rancidity and hazelnut, and less aroma of fresh meat. Their texture was drier and less mellow.